{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:18:40Z","timestamp":1768879120766,"version":"3.49.0"},"reference-count":30,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2014,12,3]]},"published-print":{"date-parts":[[2015,5,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To quantify the risk of non-fatal acute myocardial infarction (AMI) among users of allopurinol.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We carried out a population-based case\u2013control study over the period 2001\u20132007 in patients aged 40\u201390\u2005years. Patients who had prescriptions of allopurinol or an episode of AMI before the start date of follow-up were excluded from the main analysis. Allopurinol initiators were classified as current users if their last prescription ended in the 30-day window before the recorded date of AMI for cases and a random date for controls. The association between use of allopurinol and non-fatal AMI was measured through an OR and adjusted for confounding factors by an unconditional logistic regression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We identified 3171 cases of non-fatal AMI and 18\u2005525 controls. Cases had a lower prevalence of current use of allopurinol (0.82%) than controls (1.03%), yielding to an OR of 0.52 (95% CI 0.33 to 0.83). The decreased risk was driven by men (OR in men=0.44; 95% CI 0.25 to 0.76; OR in women=0.90; 0.36 to 2.23). No difference by age was observed. The effect was only observed at higher doses (300\u2005mg or greater OR=0.30; 0.13 to 0.72; &lt;300\u2005mg OR=0.67; 0.37 to 1.23) and with prolonged treatments (&lt;31\u2005days, OR=1.12 (0.55 to 2.29); 31\u2013180\u2005days, OR=0.61; 0.29 to 1.29; &gt;180\u2005days OR=0.21; 0.08 to 0.53; p for trend=0.001). Among those with a previous AMI, allopurinol use also showed a significant reduced risk of recurrence (OR=0.16; 0.04 to 0.76).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The present study supports the hypothesis that allopurinol is associated with a reduced risk of non-fatal AMI, which seems to be dose-dependent and duration-dependent.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/heartjnl-2014-306670","type":"journal-article","created":{"date-parts":[[2015,1,5]],"date-time":"2015-01-05T21:12:36Z","timestamp":1420492356000},"page":"679-685","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":44,"title":["Allopurinol use and risk of non-fatal acute myocardial infarction"],"prefix":"10.1136","volume":"101","author":[{"given":"Francisco J","family":"de Abajo","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Unit, University Hospital \u201cPr\u00edncipe de Asturias\u201d, Department of Biomedical Sciences, School of Medicine and Health Sciences, University of Alcal\u00e1, Alcal\u00e1 de Henares, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel J","family":"Gil","sequence":"additional","affiliation":[{"name":"BIFAP Research Unit, Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Agency for Medicines and Medical Devices, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, University Hospital \u201cPr\u00edncipe de Asturias\u201d, Department of Biomedical Sciences, School of Medicine and Health Sciences, University of Alcal\u00e1, Alcal\u00e1 de Henares, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Garc\u00eda-Poza","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, University Hospital \u201cPr\u00edncipe de Asturias\u201d, Department of Biomedical Sciences, School of Medicine and Health Sciences, University of Alcal\u00e1, Alcal\u00e1 de Henares, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"\u00c1lvarez","sequence":"additional","affiliation":[{"name":"BIFAP Research Unit, Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Agency for Medicines and Medical Devices, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Bryant","sequence":"additional","affiliation":[{"name":"BIFAP Research Unit, Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Agency for Medicines and Medical Devices, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis A","family":"Garc\u00eda-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Spanish Centre for Pharmacoepidemiological Research (CEIFE), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2015,1,5]]},"reference":[{"key":"2025092012180656000_101.9.679.1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.055269"},{"key":"2025092012180656000_101.9.679.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60883-7"},{"key":"2025092012180656000_101.9.679.3","doi-asserted-by":"publisher","DOI":"10.1124\/pr.58.1.6"},{"key":"2025092012180656000_101.9.679.4","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000041431.57222.AF"},{"key":"2025092012180656000_101.9.679.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(02)03144-2"},{"key":"2025092012180656000_101.9.679.6","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2012-302249"},{"key":"2025092012180656000_101.9.679.7","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/annrheumdis-2012-202972","article-title":"Impact of allopurinol on risk of myocardial infarction","volume":"74","author":"Grimaldi-Bensouda","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025092012180656000_101.9.679.8","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwg231"},{"key":"2025092012180656000_101.9.679.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1386-3"},{"key":"2025092012180656000_101.9.679.10","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3617"},{"key":"2025092012180656000_101.9.679.11","unstructured":"(WICC) International Classification of Primary Care\u20142nd Edition Wonca International Classification Committee. http:\/\/qicpd.racgp.org.au\/media\/57417\/icpc-codes.pdf (accessed 20 Oct2013)."},{"key":"2025092012180656000_101.9.679.12","doi-asserted-by":"crossref","unstructured":"Rothman K , Greenland S , Lash TS . Case-control studies. In: Rothman K , Greenland S , Lash TS, eds , 3rd edn. Philadelphia: Wolters Kluwer\/Lippincott, William & Wilkins, 2008, 111\u201327.","DOI":"10.1002\/9780470061596.risk0599"},{"key":"2025092012180656000_101.9.679.13","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Restricci\u00f3n del uso de benzbromarona (urinorm\u00ae) y suspensi\u00f3n de comercializaci\u00f3n de benziodarona (dilafurane\u00ae) y de las asociaciones benzbromarona-alopurinol (acifugan\u00ae, facilit\u00ae). http:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2004\/NI_2004-02_urinorm.htm (accessed 20 Oct 2013)."},{"key":"2025092012180656000_101.9.679.14","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3248"},{"key":"2025092012180656000_101.9.679.15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep069"},{"key":"2025092012180656000_101.9.679.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03887.x"},{"key":"2025092012180656000_101.9.679.17","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01580210"},{"key":"2025092012180656000_101.9.679.18","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.198"},{"key":"2025092012180656000_101.9.679.19","doi-asserted-by":"crossref","unstructured":"Dubreuil M , Zhu Y , Zhang Y , et al . Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis Published Online First: 24 Mar 2014. doi:10.1136\/annrheumdis-2014-205269 doi\/10.1136\/annrheumdis-2014-205269","DOI":"10.1136\/annrheumdis-2014-205269"},{"key":"2025092012180656000_101.9.679.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5922.2011.00277.x"},{"key":"2025092012180656000_101.9.679.21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119076"},{"key":"2025092012180656000_101.9.679.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60391-1"},{"key":"2025092012180656000_101.9.679.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.07.074"},{"key":"2025092012180656000_101.9.679.24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099102"},{"key":"2025092012180656000_101.9.679.25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.651117"},{"key":"2025092012180656000_101.9.679.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.10.027"},{"key":"2025092012180656000_101.9.679.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0800885"},{"key":"2025092012180656000_101.9.679.28","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.00650"},{"key":"2025092012180656000_101.9.679.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.22014"},{"key":"2025092012180656000_101.9.679.30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.703389"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2014-306670","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T19:18:14Z","timestamp":1758395894000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2014-306670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,5]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2015,4,9]]},"published-print":{"date-parts":[[2015,5,1]]}},"alternative-id":["10.1136\/heartjnl-2014-306670"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2014-306670","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,5]]}}}